Nonmyeloablative allogeneic transplantation is an emerging therapy for hematologic and solid malignancies and potentially offers patients reduced transplant-related toxicity. Data regarding infectious complications of these protocols are limited, but early studies have demonstrated little infectious morbidity, particularly low rates of invasive fungal infections (IFIs). In the present study, 31 consecutive cases of nonmyeloablative transplantation were reviewed over a 2.5-year period, with a specific focus on infectious complications. Twentysix patients (84%) had at least 1 significant infection during the year after transplantation, and infectionrelated mortality was 37%. Cytomegalovirus end-organ disease was diagnosed in 3 patients (10%). Ten patients (32%) were given the diagnosis of IFI; 7 (23%) met criteria for proven IFI. Fungal-related mortality was 80% within the group of patients with IFI and accounted for a significant portion of the overall mortality in the study. Severe graft-versus-host disease, high-dose corticosteroid use, recurrent neutropenia, and relapsed or refractory disease were factors associated with development of IFI.
Nonmyeloablative allogeneic transplantation is a relatively new, potentially less toxic alternative to conventional allogeneic stem cell transplantation (SCT) or bone marrow transplantation (BMT). This approach uses a reduced-intensity conditioning regimen, compared with conventional allogeneic SCT, to generate more-rapid engraftment and exploit the phenomenon of graft-versus-tumor effect [1, 2] . Success with this strategy has been demonstrated in patients with hematologic and nonhematologic malignancies [3] [4] [5] [6] . Harnessing the graft-versus-tumor effect, although minimizing severe graft-versus-host disease (GVHD), presents a significant challenge for physicians performing nonmyeloablative transplantation. GVHD and the associated immunosuppressive therapies increase the susceptibility to infection and the risk of poor outcomes in recipients of conventional allogeneic SCT. Limited data are available on infectious complication rates for nonmyeloablative transplants. Two series have reported increased rates of cytomegalovirus infection but no invasive fungal infections (IFIs) [7, 8] . In a different series, patients with preexisting fungal infections underwent nonmyeloablative transplantation without progression of preexisting fungal infection [9] . Some early data suggest that patients who are ineligible for conventional allogeneic SCT because of advanced age or comorbidities can safely undergo nonmyeloablative transplantation [4, 5, 9] . However, initial experience suggests that heavily pretreated patients may be particularly susceptible to increased toxicity, even in the setting of nonmyeloablative transplantation [10] . An understanding of the incidence of and risk factors for infectious complications following nonmyeloablative transplantation has important implications for the development of strategies to prevent infections in this setting. In the present study, we review the infectious complications in all consecutive patients who received nonmyeloablative allogeneic transplantation at our institution over a 2.5-year period.
PATIENTS AND METHODS
Patients. All consecutive patients who underwent nonmyeloablative conditioning, followed by allogeneic transplantation of donor peripheral blood lymphocytes or peripheral stem cells, at the University of Pennsylvania between January 1998 and September 2001 were identified. We have termed all of these procedures "nonmyeloablative allogeneic transplantations." Data collected included patient demographics, stage and type of malignancy, prior treatments, transplant match, chemotherapy and transplantation protocol, comorbidities, presence of fungal infection during the year before transplantation, severity and duration of GVHD, prophylactic and therapeutic antimicrobial use, neutropenia, infectious complications, and mortality. Treatment outcomes for a subset of these patients were reported elsewhere [10] .
With the exception of patients with chronic lymphocytic leukemia, all patients were ineligible for conventional allogeneic SCT because of age, extensive prior therapy, or comorbid disease. Patients with chronic lymphocytic leukemia may have been offered nonmyeloablative allogeneic transplantation as an alternative to conventional allogeneic BMT. Conditioning therapy included fludarabine (30 mg/m 2 ) and cyclophosphamide (300 mg/m 2 ) daily for 3 days in 20 cases. To enhance the level of immunosuppression and cytoreduction, patients who had ovarian cancer ( ) or received unrelated donor grafts n p 3 ( ) were treated with high-dose fludarabine (25 mg/m 2 / n p 5 day for 5 days) and high-dose cyclophosphamide (2 g/m 2 /day for 2 days) as conditioning therapy. Patients who received matched sibling grafts and had a diagnosis of chromic myelogenous leukemia ( ) or myelodysplastic syndrome n p 1 ( ) received high-dose cyclophosphamide (3 g/m 2 ) and n p 2 antithymocyte globulin. Allogeneic transplantation consisted of unstimulated peripheral blood donor leukocytes ( ) n p 9 or granulocyte colony-stimulating factor-mobilized peripheral blood stem cells from matched siblings ( ) or unn p 17 related donors (
). The median cell dose for all patients n p 5 was mononuclear cells/kg; for the 22 recipients of 8 4.6 ϫ 10 granulocyte colony-stimulating factor-mobilized products, the median cell dose was CD34 ϩ cells/kg. 6 4 ϫ 10 Definitions.
Fever was defined as a temperature of 138.5ЊC. Neutropenia was defined as an absolute neutrophil count of !500 cells/mL. For outpatients who were monitored with weekly blood draws and for whom no neutropenia was documented, a duration of !7 days of neutropenia was presumed. For purposes of calculations, those patients were assigned a value of 3.5 days. GVHD was considered to be acute if onset was on or before day 100 and chronic if onset was after day 100. Prednisone doses of у2 mg/kg/day (or equivalent doses of other corticosteroids) were considered as high-dose corticosteroids. Pneumonia was defined as fever with new infiltrate not interpreted as atelectasis on chest radiograph. Any isolate obtained from culture of blood was considered to be an infection unless treated as a contaminant in the medical record.
Invasive fungal infections were categorized as proven, probable, or possible, according to criteria described elsewhere [11] . Other infections were defined by standard clinical criteria. Surveillance for cytomegalovirus infection consisted of weekly serum antigenemia testing starting on day 30 and the institution of treatment with iv ganciclovir for any positive result. Cause of death was determined by autopsy when possible and by the records of the patient's attending physician at the time of death when no autopsy was done. Statistical analysis. Epi-Info software (Centers for Disease Control and Prevention) was used for all statistical analyses. Categorical variables were compared by use of x 2 tests, and was considered to be statistically significant. All tests P ! .05 were 2-sided.
RESULTS

Patients.
During the study period, 33 nonmyeloablative allogeneic transplantations were done for 32 patients. Complete records were available for 31 episodes of transplantation for 30 patients, and these constitute the study population. One patient underwent 2 transplantations, and each transplantation was considered separately ( patients). Sixteen men and 15 n p 31 women underwent transplantation; the median age at the time of transplantation was 47 years (range, 22-62 years). Twentyeight patients were treated for hematologic diseases, and 3 were treated for ovarian cancer. Twenty-two patients (71%) had refractory or relapsed disease. Twenty-six patients received transplants from matched related donors. The donor graft was sexmismatched in 14 cases, and the median donor age was 40 years (range, 21-65 years). Nonmyeloablative transplantation occurred most often in the outpatient setting (
). There n p 23 were no documented or suspected fungal infections in the year before any transplantation. The median length of follow-up was 203 days (range, 18-1376 days). Baseline characteristics of the patients are shown in table 1.
Antimicrobial prophylaxis and empirical therapy. Complete data about antifungal prophylaxis were not available for many of the patients. For 18 patients, prophylaxis with fluconazole or itraconazole was documented at some point during the posttransplantation course. Most received it before day 100. Thir- Table 2 .
Graft-versus-host disease (GVHD) incidence, prophylaxis, and severity among patients in a study of invasive fungal infections after nonmyeloablative allogeneic transplantation. teen patients had no documentation of antifungal prophylaxis. Twenty-two patients received prophylaxis for Pneumocystis carinii pneumonia with either trimethoprim-sulfamethoxazole or dapsone. Eleven patients received acyclovir as prophylaxis for herpes simplex virus. Empirical or definitive antimicrobial therapy was common in the first 30 days, with 20 patients receiving antibacterial therapy (11 broad-spectrum), 11 receiving antifungal therapy, and 5 receiving antiviral therapy. Neutropenia and neutropenic fever. The median duration of initial transplantation-associated neutropenia was 6 days (range, 0-17 days), with nearly half of the patients experiencing neutropenia for !7 days. Febrile neutropenia was minimal during the first 30 days and occurred in only 11 patients (35%); the median duration of neutropenia was 2 days among those patients. Twelve patients (39%) had confirmed recurrent neutropenia after day 30.
GVHD. Twenty patients developed acute and/or chronic GVHD. Table 2 details the prophylaxis, severity, and duration of therapy for these cases. Severe, grade III/IV acute GVHD developed in 11 patients (35%). Treatment regimens included corticosteroids for most patients ( ) and, for some, caln p 15 cineurin inhibitors (cyclosporine or tacrolimus), mycophenolate mofetil, monoclonal antibodies, and antithymocyte globulin. More than half of the patients with GVHD received prolonged courses of high-dose corticosteroids. Duration of therapy was у3 weeks in most cases (range, 16 to 1150 days).
Infections. Table 3 shows the nonfungal infections after transplantation. Disseminated viral infection was confirmed for 3 patients: 2 with herpes simplex virus and 1 with varicella zoster virus. Two of these 3 patients also had concomitant IFI, diagnosed by autopsy.
Fungal infections. IFI was diagnosed in 10 (32%) of 31 patients (95% CI, 17%-51%) following nonmyeloablative transplantation. Details of these cases are presented in table 4. Seven patients (23%) met criteria for proven, 1 for probable, and 2 for possible IFI. Aspergillus species were the most common pathogen. Initial presentation occurred at a median of 81 days (range, 11-175 days) after transplantation, with the majority ( ) occurring after engraftment. Few patients n p 8 ( ) were neutropenic at the time of presentation. Six of n p 3 the 10 patients with IFI had received antifungal prophylaxis previously, and 4 of these patients were receiving fluconazole prophylaxis at the time of presentation with IFI. In 6 of 8 patients with proven or probable IFI, the diagnosis was sus- pected, and empirical antifungal therapy administered, before confirmation. Two patients did not receive empirical therapy because there was little or no clinical suspicion of IFI. One of these patients was given the diagnosis of disseminated mucormycosis only at autopsy. For the 9 patients with IFI suspected or confirmed premortem, the median delay from time of original presentation to start of empirical or definitive antifungal therapy was 4 days (range, 0-14 days). Nine of 10 patients with IFI were receiving corticosteroids at the time of presentation and/or diagnosis.
We evaluated multiple potential risk factors for evidence of association with IFI, including underlying malignancy, disease status at time of transplantation, prior autologous BMT or SCT, transplantation regimen and setting (inpatient vs. outpatient), donor-recipient match, neutropenia, GVHD, corticosteroid use, cytomegalovirus coinfection, and antifungal prophylaxis. On univariate analysis, statistically significant associations between development of IFI and the following were found: grade III/IV GVHD (relative risk [RR], 4.2; 95% CI, 1.4-13), corticosteroid use, particularly high-dose (RR, 4.3; 95% CI, 1.62-11.45), recurrent neutropenia after day 30 (RR, 6.3; 95% CI, 1.6-24.9), and refractory or relapsed disease at transplantation (RR, 82; 95% CI, 34-197). Of note, there was no association demonstrated between antifungal prophylaxis and diagnosis of IFI.
Outcomes. After nonmyeloablative transplantation, 7 patients achieved a complete remission (23%), and 10 achieved a partial remission (32%), for an overall response rate of 55%. Five patients were not evaluable, 2 patients had stable disease, and 7 patients did not respond and had progressive disease. Overall survival rates on day 30 and day 100 were 90% and 74%, respectively. The 1-year mortality rate for the study population was 52% (2 patients for whom !1 year had elapsed since transplantation were not included). Ten patients (32%) died of disease progression, whereas 11 patients died of treatment-related causes (GVHD and/or infection); no patient died of direct regimen-related toxicity. Two patients died while in complete remission, and 5 patients died after a partial remission from treatment-related complications. At the time of last follow-up, 3 patients (10%) were alive and in complete remission, 4 (13%) were alive with stable partial remission, and 3 (10%) were alive with active disease. Overall mortality with a median follow-up of 203 days was 70%. Overall infection-related mortality was 37% (52% of total mortality). Specifically, fungalrelated mortality was 23% (33% of overall mortality). Within the group of patients with IFI, fungal-related mortality was 80%, and overall mortality was 100%.
DISCUSSION
This study is, to our knowledge, the largest series in the literature addressing infectious complications following nonmyeloablative transplantation. As many patients died of infection as of disease progression in this series.
As others have noted, the duration of initial neutropenia with nonmyeloablative regimens was short, and few serious infections occurred in the early posttransplantation period. Of note, however, a large number of patients in our series developed recurrent neutropenia after engraftment, and the reason for this is unclear.
The most significant findings in our study were an exceptionally high rate of IFI (32%) and a large proportion of overall mortality attributable to these IFIs. Even a conservative assessment of 23% incidence of IFI (including only proven cases [ ]) is in stark contrast to the complete absence of IFIs n p 7 reported in other series studying infectious complications of nonmyeloablative transplantation [7, 8] . This high incidence of IFI also exceeds that seen in conventional allogeneic BMT/ SCT studies (6%-18%) [3, [12] [13] [14] [15] [16] . The difficulties in diagnosing IFI after BMT/SCT are well known, with autopsy series revealing that a diagnosis is often made only by postmortem examination [17] . It is, therefore, entirely possible that our estimate of the rate of IFI is an underestimate. In this series, several significant associations with IFI were demonstrated. Grade III/IV GVHD, refractory or relapsed disease, recurrent neutropenia, and high-dose corticosteroid use were associated with increased risk. These findings are consistent with well-established risk factors for IFI in conventional allogeneic BMT literature [14, 15, 18] . Compared with the nonmyeloablative transplantation populations studied by both Mohty et al. [7] and Mossad et al. [8] , in which no IFIs were identified, our population had a higher prevalence of these risk factors. Specifically, grade III/IV GVHD occurred in 35% of our patients, compared with rates of 5%-25% [7, 8] . Refractory or relapsed disease, present in 71% of our population, was also more prevalent than in the patients studied by Mohty et al. [7] (60%) and Mossad et al. [8] (33%). We believe that the relative preponderance of these risk factors in our population, compared with those previously studied, may account, in part, for the dramatic differences in IFI rates. It is possible that we were able to establish a diagnosis of IFI more readily by use of aggressive diagnostic techniques, but the lower overall mortality rate in the previous series makes this unlikely. It is also possible that high rates of previous cancer therapies in our patients may have increased the likelihood of subclinical fungal infection before transplantation or that environmental exposures at our center differed from those encountered by the patients in the previous series. However, an incidence of invasive mold infection of just 11.5% (authors' unpublished data) in our conventional allogeneic BMT/SCT population (who also standardly received fluconazole) within the study time frame makes this less likely. For the same reason, we do not believe that the high IFI rate among our nonmyeloablative transplant patients is related to environmental exposure or transplantation-specific supportive care unique to our institution.
It is possible that differences in antifungal prophylaxis regimens among programs might lead to differences in IFI rates. Patients in the prior series received either thrice-weekly amphotericin B during the first 3 months after transplantation [7] , itraconazole followed by amphotericin (if taking prednisone doses of у40 mg b.i.d.) 3 times weekly [8] , or amphotericin B and prophylactic granulocyte transfusions [9] . The antifungal prophylaxis regimen for most of our patients was fluconazole. All the IFIs we studied, with the exception of Candida glabrata infection in 1 patient, were due to molds and would not have been prevented by fluconazole prophylaxis. Trials of antifungal prophylaxis after BMT/SCT are quite limited. Several randomized studies reveal the efficacy of fluconazole (400 mg daily) in reducing IFI [19] [20] [21] [22] . The longest of these trials, however, continued the prophylaxis until day 75 [20] . In our series, IFI developed at a median of 81 days after transplantation.
Importantly, the median delay from presentation of IFI to implementation of appropriate treatment was only 4 days, yet the mortality attributed to IFI among those patients was 80%. It is well known, in this patient population [12, 13, 18] , that once IFI is established, outcomes are poor, regardless of therapy. Clearly, better prophylaxis against molds is needed for nonmyeloablative transplant recipients, particularly those with GVHD. Longer, multicenter trials that carefully evaluate risk factors are needed. Clinical trials that examined liposomal amphotericin B and low-dose amphotericin B deoxycholate have been limited [23] [24] [25] . These agents are also cumbersome to administer during what is often a long at-risk period and are associated with significant toxicity. Itraconazole, voriconazole, and the new echinocandins are potentially attractive candidates.
Our study has several important limitations. The large 95% CIs reflect our small sample size. Because it was a single-center study, patient selection may explain our findings and limit generalizability. Finally, the retrospective study design may permit bias.
Nonmyeloablative transplantation is an emerging and exciting therapy. Very little has been described regarding infectious complications of this procedure. This population is clearly different from the standard allogeneic SCT recipient population (given the high rate of refractory and previously treated disease, older age, and comorbid disease). The risks of infectious and other complications require special study and cannot be extrapolated from conventional allogeneic SCT experience.
The rates of IFI in our study are concerning. Additional analysis with larger groups of patients will better elucidate the risk factors for IFI specific to this population. Prospective studies on the incidence of infectious complications following nonmyeloablative transplantation and the use of antifungal prophylaxis are clearly needed.
